

The logo for Seeking Alpha, with the text 'Seeking Alpha' in white and a gold Greek letter alpha symbol to the right, all on a dark red background.

## Human Genome Sciences Inc. Q2 2008 Earnings Call Transcript

### Question-and-Answer Session

---

#### Operator

(Operator Instructions). We will take our first question from Ted Tenthoff with Piper Jaffray.

#### Ted Tenthoff - Piper Jaffray

Great. Thank you very much. If I may on ABthrax, you've been pretty consistent in saying that we will be giving the beginning of that delivery this fall. Can you just give us a little bit more clarity, either on the timing, or how we should expect to see this rollout? In other words will it be pressed released, or will it just be on the [SEDAR], will be it one lump-sum? What additional information can you give us there?

#### H. Thomas Watkins

Let me ask Jim Davis to speak to that question. Thanks.

#### Ted Tenthoff - Piper Jaffray

Thanks, Tom.

#### Jim Davis

Sure. This is Jim. We are, obviously, in the process of working closely with FDA and BARDA to have the data that we submitted to FDA fully reviewed. As we said we expect to begin delivery this fall. My expectations, though I would say, there has been no final decision, is that we would issue a press release upon the actual first delivery of product to National Stockpile. It will not be at one time. It will be overtime, if and whether reasons of security, you do not want all your products on one truck or at one delivery time. So we will be delivering over the course of the latter part of this year, and into next year.

#### Ted Tenthoff - Piper Jaffray

Okay. Thank you.

#### Operator

Our next question comes from your Yaron Werber with Citi.

#### Unidentified Analyst

Hi, this is actually [Coreen Dephilipe] calling in for Yaron. I have a question, if you give us an update on your partnering plans for the ETR1 antibody, have you been in talks with anyone, or you intend to wait for the Phase 3 data in the third quarter? Thank you.

**H. Thomas Watkins**

I am going to ask Barry Labinger to comment on that. Barry?

**Barry Labinger**

Yes. As we said when we announced the reacquisition of our rights to TRAIL receptor antibodies from GSK, we have begun to explore potential new partnerships that are more ideally structured to support the program. So we have started that process to reach out into the oncology community. And I think it is fair to say that we have had our expectations confirmed that the TRAIL induced apoptosis pathway is a hot area.

Copyright © 2008 CNET Networks, Inc. All Rights Reserved.